Adaptive Biotechnologies get expanded medicare coverage of clonoSEQ for assessing measurable residual disease in mantle cell lymphoma: Seattle Saturday, November 9, 2024, 15:00 Hr ...
Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...
The detection of CTCs holds significant promise for early-stage ... Furthermore, CTCs are particularly useful in monitoring ...
In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...
NEW YORK – Adaptive Biotechnologies announced on Thursday that its blood-based ClonoSeq assay has received expanded coverage from Medicare administrative contractor Palmetto GBA for the detection and ...
Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...
a minimal residual disease (MRD) detection solution showcasing a limit of detection (LOD) down to one-in-a-million. MRDVision combines Inocras’s WGS cancer profiling platform, CancerVision, and Ultima ...
Littelfuse’s RCMP20 residual current monitors support compact, high-current Mode 2 and Mode 3 EV charging stations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback